Health-Related Quality of Life as Measured by the 36-Item Short Form Survey Among Adults With Acute Bacterial Skin and Skin Structure Infections who Received Either Omadacycline or Linezolid in a Phase 3 Double-Blind, Double-Dummy Clinical Trial

Surya Chitra; Jordan Hinahara; Thomas F Goss; Kyle Gunter; Kenneth LaPensee

doi:10.1093/ofid/ofab459

Health-Related Quality of Life as Measured by the 36-Item Short Form Survey Among Adults With Acute Bacterial Skin and Skin Structure Infections who Received Either Omadacycline or Linezolid in a Phase 3 Double-Blind, Double-Dummy Clinical Trial

Open Forum Infect Dis. 2021 Sep 8;8(10):ofab459. doi: 10.1093/ofid/ofab459. eCollection 2021 Oct.

Authors

Surya Chitra¹, Jordan Hinahara², Thomas F Goss², Kyle Gunter¹, Kenneth LaPensee¹

Affiliations

¹ Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
² Boston Healthcare Associates, Inc., Boston, Massachusetts, USA.

Abstract

This analysis of data from a Phase 3 study of adults with acute bacterial skin and skin structure infections showed that successful oral treatment with omadacycline (n = 368) or linezolid (n = 367) was associated with improvement in health-related quality of life.

Keywords: ABSSSI; acute bacterial skin and skin structure infections; omadacycline; patient-reported outcome measures; quality of life.